Director/PDMR Shareholding
Summary by AI BETAClose X
ValiRx PLC
("ValiRx" or the "Company")
Director/PDMR Shareholding
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it received notification on 3 March 2026 that Mark Eccleston, Chief Executive Officer, made the following purchase of ordinary shares in the Company.
|
Director |
Purchase price (Aggregated) |
Ordinary shares purchased |
Resultant interest in ordinary shares |
Resultant percentage of issued ordinary shares |
|
Mark Eccleston |
0.33 pence |
1,000,000 |
59,746,187 |
8.04% |
Further details are set out in the Notification of Dealing Form below.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
|
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 115 784 0026 Mark.Eccleston@valirx.com
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath |
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
|
+44 (0) 115 787 0206
lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the persons discharging managerial responsibilities / person closely associated
|
|||||
|
a) |
Name
|
Mark Eccleston |
||||
|
2 |
Reason for the notification
|
|||||
|
a) |
Position/Status
|
Chief Executive Officer |
||||
|
b) |
Initial notification/ Amendment
|
Initial |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a) |
Name
|
ValiRx PLC |
||||
|
b) |
LEI
|
213800VQKB9SJCQDET40 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares
GB00BLH13C52 |
||||
|
b) |
Nature of the transaction |
Purchase of shares
|
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d) |
Aggregated information
- Aggregated volume
- Price
|
N/A
|
||||
|
e) |
Date of transaction
|
3 March 2026 |
||||
|
f) |
Place of transaction
|
AIM |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 minutes ago Personal Group Holdings
- 8 minutes ago Grainger
- 36 minutes ago Helios Underwriting
- 57 minutes ago SSE
- 2 hours ago Judges Scientific